Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label imlifidase plus IVIg study in Guillain-Barré syndrome
NL-OMON52611Phase 2Completed
- Sponsor
- Hansa Biopharma
- Start
- Feb 2023
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of imlifidase in Guillain-Barré syndrome (GBS) (2 arms), sponsored by Hansa Biopharma. Primary endpoint: Safety and tolerability. Started Feb 2023; status: completed.
02
Drugs
imlifidase
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NL-OMON52611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52611.